Double maintains 2 strategies that include KYMR - Kymera Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 62.78% | $4.95B | 0.35% |
GNOM | 58.41% | $44.43M | 0.5% |
IBB | 56.07% | $5.36B | 0.45% |
ARKG | 55.49% | $1.05B | 0.75% |
IWO | 51.43% | $11.48B | 0.24% |
PBE | 51.15% | $223.24M | 0.58% |
IWC | 50.77% | $824.65M | 0.6% |
PTH | 49.95% | $101.07M | 0.6% |
XPH | 49.63% | $149.79M | 0.35% |
IWM | 49.22% | $64.00B | 0.19% |
VTWO | 49.05% | $13.29B | 0.07% |
KJAN | 48.23% | $289.38M | 0.79% |
PINK | 48.14% | $133.06M | 0.5% |
SCHA | 47.91% | $17.26B | 0.04% |
ISCG | 47.74% | $679.06M | 0.06% |
RDTE | 47.38% | $138.47M | 0.97% |
VBK | 47.29% | $18.97B | 0.07% |
QQQJ | 47.02% | $617.03M | 0.15% |
KOMP | 46.93% | $2.28B | 0.2% |
SMMD | 46.87% | $1.51B | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NRIX | 65.41% | $887.38M | -44.23% | 0.00% |
VERA | 60.60% | $1.44B | -37.40% | 0.00% |
BPMC | 52.67% | $8.28B | +18.86% | 0.00% |
RVMD | 52.33% | $6.88B | -4.90% | 0.00% |
VYGR | 51.49% | $163.80M | -62.58% | 0.00% |
CGON | 50.89% | $1.98B | -17.80% | 0.00% |
CRNX | 50.69% | $2.81B | -33.11% | 0.00% |
XENE | 49.66% | $2.49B | -16.90% | 0.00% |
IDYA | 49.56% | $1.87B | -39.13% | 0.00% |
IMVT | 49.02% | $2.75B | -39.02% | 0.00% |
DNLI | 49.01% | $2.05B | -39.28% | 0.00% |
RGNX | 48.98% | $422.76M | -28.29% | 0.00% |
VTYX | 48.55% | $166.52M | +1.30% | 0.00% |
BNTX | 48.51% | $25.65B | +32.80% | 0.00% |
IMNM | 47.92% | $763.10M | -27.52% | 0.00% |
KURA | 47.42% | $490.88M | -72.46% | 0.00% |
DYN | 47.25% | $1.09B | -72.88% | 0.00% |
RNA | 47.17% | $3.50B | -28.94% | 0.00% |
NUVL | 47.05% | $5.72B | +5.04% | 0.00% |
RARE | 46.72% | $3.45B | -11.14% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TEF | 0.02% | $29.29B | +23.28% | 6.30% |
TXMD | -0.08% | $12.96M | -30.43% | 0.00% |
GO | 0.11% | $1.24B | -42.90% | 0.00% |
MCD | 0.16% | $208.47B | +14.41% | 2.39% |
NEUE | -0.21% | $61.96M | +27.57% | 0.00% |
T | -0.24% | $202.05B | +46.94% | 3.95% |
KDP | 0.27% | $44.62B | -1.65% | 3.46% |
DFDV | 0.28% | $247.94M | +1,821.34% | 0.00% |
OXBR | -0.32% | $13.03M | -26.47% | 0.00% |
CNK | 0.36% | $3.46B | +39.22% | 0.53% |
BTCT | 0.38% | $18.98M | +37.85% | 0.00% |
VHC | 0.40% | $45.90M | +59.26% | 0.00% |
CPSH | 0.49% | $40.67M | +64.71% | 0.00% |
NOC | -0.52% | $71.10B | +13.32% | 1.72% |
DG | -0.55% | $25.19B | -13.45% | 2.07% |
CHD | 0.68% | $23.34B | -8.58% | 1.22% |
EDU | -0.68% | $8.85B | -29.65% | 0.00% |
PRMB | -0.71% | $11.05B | +38.59% | 1.30% |
PPC | 0.74% | $10.57B | +30.66% | 0.00% |
GIS | 0.75% | $27.66B | -20.14% | 4.74% |
Yahoo
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera’s innovative molecular glue degrader/MGD […]
Yahoo
Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.
Yahoo
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common sto
Yahoo
Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following “a slate of updates,” including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is “disappointing and removes potential catalysts” next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader pa
Yahoo
Futures are flat to slightly higher as the Israel‑Iran ceasefire remains stable and investor focus shifts to another day of testimony from Fed Chair Powell. Oil prices have steadied around $65-$66 per barrel after a recent drop, easing inflation pressures and supporting equities. Treasury yields and the dollar have softened, buoyed by speculation that the Fed may cut rates as soon as July or September. Equities closed near record highs yesterday as tech remains in favor, led by chipmakers such a
Current Value
$45.021 Year Return
Current Value
$45.021 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TFI | -<0.01% | $3.21B | 0.23% |
GSST | -0.02% | $918.38M | 0.16% |
BAB | -0.05% | $931.18M | 0.28% |
TAXF | 0.05% | $488.44M | 0.29% |
SHYD | -0.09% | $332.20M | 0.35% |
GOVI | -0.23% | $927.22M | 0.15% |
AGGH | 0.24% | $323.99M | 0.29% |
FLMI | -0.24% | $722.98M | 0.3% |
SMB | -0.27% | $274.71M | 0.07% |
FLDR | 0.29% | $944.21M | 0.15% |
JMUB | 0.38% | $3.03B | 0.18% |
MMIT | -0.48% | $1.02B | 0.3% |
JPLD | -0.53% | $1.76B | 0.24% |
SHM | -0.53% | $3.41B | 0.2% |
XBIL | 0.57% | $783.57M | 0.15% |
BUXX | -0.64% | $318.71M | 0.25% |
GOVT | -0.64% | $27.51B | 0.05% |
HYMB | -0.65% | $2.62B | 0.35% |
IBMS | -0.66% | $88.22M | 0.18% |
BNDX | 0.67% | $67.37B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -39.93% | $296.79M | 1.43% |
VIXY | -38.34% | $165.69M | 0.85% |
TAIL | -38.11% | $99.76M | 0.59% |
IVOL | -19.77% | $349.27M | 1.02% |
XONE | -12.67% | $585.86M | 0.03% |
SHYM | -12.00% | $350.04M | 0.35% |
SPTS | -9.88% | $5.78B | 0.03% |
UTWO | -9.84% | $379.36M | 0.15% |
DFNM | -9.81% | $1.56B | 0.17% |
SCHO | -9.40% | $11.46B | 0.03% |
BILS | -9.40% | $3.86B | 0.1356% |
AGZ | -9.24% | $614.02M | 0.2% |
TBLL | -8.64% | $2.13B | 0.08% |
CLIP | -8.48% | $1.52B | 0.07% |
USDU | -7.84% | $162.92M | 0.5% |
VGSH | -7.60% | $22.80B | 0.03% |
KCCA | -7.58% | $105.63M | 0.87% |
IBTI | -7.53% | $1.06B | 0.07% |
UUP | -7.22% | $211.55M | 0.77% |
BSMW | -7.12% | $107.26M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -13.46% | $23.98B | +34.66% | 1.10% |
ED | -10.24% | $35.36B | +9.76% | 3.39% |
CIG.C | -8.67% | $2.64B | +19.84% | 0.00% |
KMB | -7.42% | $42.44B | -7.46% | 3.88% |
VSTA | -7.07% | $342.46M | +40.00% | 0.00% |
LITB | -6.53% | $21.70M | -78.27% | 0.00% |
K | -6.52% | $27.41B | +36.96% | 2.88% |
SAIC | -6.31% | $5.12B | -7.07% | 1.36% |
EXC | -5.58% | $43.32B | +23.98% | 3.65% |
CME | -4.81% | $99.01B | +39.76% | 3.87% |
CL | -4.55% | $71.89B | -8.58% | 2.28% |
ZCMD | -4.47% | $28.79M | -13.64% | 0.00% |
DUK | -4.19% | $90.88B | +16.65% | 3.59% |
CREG | -4.15% | $5.81M | -77.49% | 0.00% |
AQB | -4.13% | $2.84M | -54.35% | 0.00% |
AIFU | -3.99% | $6.13B | +82.50% | 0.00% |
VSA | -3.78% | $8.67M | -15.70% | 0.00% |
AMT | -3.59% | $101.95B | +12.04% | 3.05% |
EZPW | -3.46% | $749.29M | +30.09% | 0.00% |
PG | -3.28% | $374.80B | -3.07% | 2.56% |